Cardiff Oncology Inc.

Last updated September 27, 2026

Organization details

Legal name
Cardiff Oncology Inc.
Former names
Trovagene, Inc. Xenomics Inc Used KAR Parts Inc
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
SAN Diego
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
CRDF
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001213037
EIN
27-2004382

Board of directors

Chief executives

Mark Erlander · Chief Executive Officer
Dates unknown
Mani Mohindru · Interim CEO Interim
Dates unknown

Director election results

Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

3 of this board's directors also sit on 3 other boards. 3 are in the same sector.

Network of Cardiff Oncology Inc.'s board connections ANI Pharmaceuticals Inc. ANI Pharmaceuticals In... CytomX Therapeutics Inc. CytomX Therapeutics In... Pacira BioSciences Inc. Pacira BioSciences Inc... Gary W. Pace Gary W. Pace Mani Mohindru Mani Mohindru Renee P. Tannenbaum Renee P. Tannenbaum Cardiff Oncology Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$1,120,098
4 purchases by 2 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jul 14, 2026 Mani Mohindru Director, Officer (Chief Executive Officer) Open-market purchase +34,364 $1.46 $50,171
Jul 14, 2026 Gary W. Pace Director Open-market purchase +687,285 $1.46 $1,003,436
Jun 18, 2026 Mani Mohindru Director, Officer (Chief Executive Officer) Open-market purchase +24,703 $1.21 $29,891
Jun 18, 2026 Gary W. Pace Director Open-market purchase +30,000 $1.22 $36,600
Jul 30, 2025 Gary W. Pace Director Open-market purchase +275,000 $2.45 $673,750
Jul 30, 2025 Gary W. Pace Director Open-market purchase +15,000 $2.45 $36,750
Dec 18, 2024 Levine James E. Officer (Chief Financial Officer) Open-market purchase +2,400 $5.00 $12,000
Dec 17, 2024 Levine James E. Officer (Chief Financial Officer) Open-market purchase +2,752 $5.42 $14,916
Dec 16, 2024 Levine James E. Officer (Chief Financial Officer) Open-market purchase +2,564 $3.83 $9,820
Dec 12, 2024 Renee P. Tannenbaum Director Open-market purchase +10,000 $3.42 $34,200
Dec 11, 2024 Gary W. Pace Director Open-market purchase +350,115 $2.60 $910,299
Dec 11, 2024 Gary W. Pace Director Open-market purchase +11,500 $2.60 $29,900
Dec 19, 2023 Gary W. Pace Director Open-market purchase +30,000 $1.37 $41,100
Nov 10, 2023 Gary W. Pace Director Open-market purchase +22,950 $0.98 $22,491

Organizations in the same sector, closest in location and size first.

Questions about Cardiff Oncology Inc.

Who is the CEO of Cardiff Oncology Inc.?

Mark Erlander is Cardiff Oncology Inc.'s Chief Executive Officer.

How many directors are on Cardiff Oncology Inc.'s board?

Cardiff Oncology Inc.'s board has 7 directors: Gary W. Pace, James O. Armitage, Lale White, Mani Mohindru, Mark Erlander, Renee P. Tannenbaum and Rodney S. Markin.

Are Cardiff Oncology Inc. insiders buying or selling shares?

Over the last 12 months, Cardiff Oncology Inc. insiders bought $1.1 million of shares in 4 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="cardiff-oncology-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.